Proliferation of human peripheral blood mononuclear cells during calcium channel blockade

American Journal of Hypertension

Volumn 11, Issue 12, 1998, Pages 1461-1468

  Lijnen, Paul ^a,b   Fagard, Robert ^a   Petrov, Victor ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Mibefradil; Mononuclear cells; Nifedipine; Proliferation

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; CALCIUM CHANNEL BLOCKING AGENT; MIBEFRADIL; NIFEDIPINE;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; HUMAN; HUMAN CELL; HYPERTENSION; MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; GALLIC ACID; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIBEFRADIL; NIFEDIPINE; SULFONAMIDES; TETRAHYDRONAPHTHALENES; TIME FACTORS;

EID: 0032417911     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00179-4     Document Type: Article

References (31)

1. Bühler F.R., Fleckenstein-Grün G. A new class of calcium antagonists from molecular biology to clinical benefit . J Cardiovasc Pharmacol. 27:1996;S1-S26.
2. Oparil S., Kobrin I., Abernethy D.R., et al. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens. 10:1997;735-742.
3. Viskoper R.J., Bernink P.J.L.M., Schelling A., et al. A randomised, double-blind trial comparing mibefradil and amlodipine two long-acting calcium antagonists with similar efficacy but different tolerability profiles . J Hum Hypertens. 11:1997;387-393.
4. Frolich E.D., Reid J. The importance of T-channel blockade in the treatment of hypertension. J Hypertens. 15:1997;S1-S42.
5. 2+ channel in cardiac tissue. Eur J Pharmacol. 290:1995;155-158.
6. 2+ channels by Ro 40-5967. Circ Res. 75:1994;144-148.
7. Lijnen P., Saavedra A., Petrov V. In vitro proliferative response of human peripheral blood mononuclear cells to concanavalin A. Clin Chim Acta. 264:1997;91-101.
8. Korzeniewski C., Callewaert D.M. An enzyme-release assay for natural cyclotoxicity. J Immunol Methods. 64:1983;313-320.
9. Stevens C., Lipman M., Fabry S., et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Therap. 272:1995;399-406.
10. Gillies R.J., Diedier N., Denton M. Determination of cell number in monolayer cultures. Anal Biochem. 159:1986;109-113.
11. Schmitt R., Clozel J.P., Iberg N., Bühler F.R. Mibefradil prevents neointima formation after vascular injury in rats. Arterioscler Thromb Vasc Biol. 15:1995;1161-1165.
12. 2 receptor modulates T-type calcium current in nondifferentiated NG108-15 cells. FEBS Lett. 209:1992;161-164.
13. Furukawa T., Ito H., Nitta J., et al. Endothelin-1 enhances calcium entry through T-type calcium channels in cultured neonatal rat ventricular myocytes. Circ Res. 71:1992;1242-1253.
14. 2+ influx via T-type channels modulates PDGF-induced replication of mouse fibroblasts. Am J Physiol. 865:1993;C1239-C1246.
15. 2+-current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res. 73:1993;777-782.
16. 2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res. 75:1994;149-155.
17. Xu X., Best P.M. Postnatal changes in T-type calcium current density in rat atrial myocytes. J Physiol (London). 45:1992;657-672.
18. Mercadier J.J., Lompre A.M., Wisnewsky C., et al. Myosin isoenzymic changes in several models of rat cardiac hypertrophy. Circ Res. 49:1981;525-532.
19. Perez-Reyes E., Cribb L.L., Daud A., et al. Molecular characterization of a neuronal low-voltage-activated T-type calcium channel. Nature. 391:1998;896-900.
20. Hérembert T., Zhu D.L., Marche P. Mechanism of action of the inhibitory effect of nifedipine on the growth of cultured aortic cells from spontaneously hypertensive and normotensive rats. Br J Pharmacol. 114:1995;1703-1709.
21. Jackson C.L., Schwartz S.M. Pharmacology of smooth muscle replication. Hypertension. 20:1992;713-736.
22. Uehara Y., Kawabata Y., Hirawa N., et al. OPC-13340, a new dihydropyridine calcium channel blocker attenuates rapid vascular smooth muscle cell growth in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 20:1992;408-415.
23. Witkowski J.M., Siebert J., Lukaszuk K., Trawicka L. Comparison of the effect of a panel of membrane channel blockers on the proliferative, cytotoxic and cytoadherence abilities of human peripheral blood lymphocytes. Immunopharmacol. 26:1993;53-63.
24. 2+ antagonist, 8-(N,N-diethylamino)-octyl-3,4,5-trimethoxybenzoate hydrochloride (TMB-8) studies in smooth muscles . Eur J Pharmacol. 27:1974;25-33.
25. Jackson C.L., Bush R.C., Bowyer D.E. Mechanism of antiatherogenic action of calcium antagonism. Atherosclerosis. 80:1989;17-26.
26. Overturf M. Are calcium ion antagonists effective anti-atherogenic agents? Arteriosclerosis. 10:1990;961-962.
27. Corcos T., David P.R., Guiteras P., et al. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. Am Heart J. 109:1985;926-931.
28. Lichtlen R.R., Hugenholtz P.G., Rafflenbeul W., et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet. 535:1996;1659-1663.
29. El-Sanadiki M.N., Cross S., Murray J.J., et al. Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment. Ann Surg. 212:1996;87-96.
30. Pelisson-Guyotat I., Guyotat J., Lievre M., Chignier E. Effect of nimodipine on subintimal hyperplasia of autologous vein bypass grafts in rats. A placebo-controlled study. J Cardiovasc Pharmacol. 17:1991;778-785.
31. Lijnen P, Fagard R, Petrov V, Van Hoof R: Cytosolic calcium and lymphoproliferation response during calcium antagonism in men. Eur J Clin Pharmacol (in press).